Owkin is a pioneering company in the healthcare and biotechnology sector, specializing in AI-powered diagnostics and drug development. The company leverages advanced machine learning and biological insights to streamline and de-risk clinical trials, thereby accelerating the drug development process. Owkin serves a diverse clientele, including leading biopharma companies and top academic centers, by providing AI-driven solutions that integrate seamlessly into digital pathology workflows for accurate and timely diagnosis. The company operates in the global healthcare market, focusing on oncology and other critical disease areas. Owkin's business model revolves around partnerships and collaborations, offering bespoke AI models and multimodal patient data to enhance clinical trial recruitment and outcomes. Revenue is generated through strategic alliances, research collaborations, and the provision of AI diagnostics and data services.

Keywords: AI diagnostics, drug development, clinical trials, digital pathology, machine learning, oncology, biopharma, multimodal data, precision medicine, healthcare innovation.